Education
About Us
Working with TipRanks
Follow Us
Argent Biopharma (RGTLF)
OTHER OTC:RGTLF
RGTLF Stock Chart & Stats
$0.10
$0.00(0.00%)
At close: 4:00 PM EST
$0.10
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.15
Previous CloseN/A
Volume49.00
Average Volume (3M)314.00
Market Cap
$3.27M
Enterprise Value$12.65M
Total Cash (Recent Filing)$1.02M
Total Debt (Recent Filing)$8.29M
Price to Earnings (P/E)―
Beta-0.99
Next Earnings
Feb 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding86,942,314
10 Day Avg. Volume254
30 Day Avg. Volume314
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap3.87
Enterprise Value/Revenue109.90
Enterprise Value/Gross Profit-154.88
Enterprise Value/Ebitda-3.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross MarginA material gross margin improvement in 2025 suggests the company achieved better pricing or a higher-margin product mix. Sustained higher gross margins support a clearer path to operating leverage and eventual profitability if revenue can stabilize or grow, strengthening long-term margin sustainability.
Less-negative Free Cash Flow TrendAn improvement in free cash flow versus the prior year indicates the company is reducing its cash burn. If this trend continues, it lowers reliance on external financing, improves survivability through near-term stress, and signals progress toward self-funded operations over the medium term.
Industry Exposure: Specialty & Generic DrugsOperating in specialty and generic pharmaceuticals provides structural demand and product differentiation opportunities. Durable industry characteristics—patent cycles, recurring prescriptions, and clinical/regulatory barriers—can support long-term revenue visibility for companies that secure product-market fit.
Bears Say
Severe Revenue ContractionA near-80% decline in revenue over the reported period indicates a collapse in scale that undermines unit economics and the ability to cover fixed costs. Persistent top-line shrinkage makes sustaining R&D, commercial investment, and progress toward profitability much harder over the medium term.
Negative Shareholders' Equity & Rising LeverageNegative equity and increasing debt signal elevated financial fragility and limited balance-sheet capacity to absorb shocks. This structure raises dependence on external funding, increases dilution or refinancing risk, and constrains strategic flexibility across a 2–6 month horizon and beyond.
Persistent Cash BurnConsistent, material negative free cash flow and near-zero operating cash flow demonstrate the business is not self-funding. Ongoing cash burn forces recurring financing, heightens dilution/default risk, and limits the company's ability to invest in growth or weather downturns without new capital.
Argent Biopharma News
RGTLF FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is $3.27M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Feb 27, 2026 which is in 3 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Aug 29, 2025. The company reported -$0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.056.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 86,942,314 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -$0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in RGTLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
RGTLF Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-77.55%
Trailing 12-Months
Company Description
Argent Biopharma
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Technical Analysis
Genetic Technologies
―
Zelira Therapeutics
―
EVE Health Group Limited
―
Adherium Ltd.
―
Bio-Gene Technology Ltd.
―